Rigel Pharmaceuticals

+0.12 (+10.18%)
5:06:10 PM EDT: $1.22 -0.03 (-2.01%)
Products, Regulatory, Earnings Announcements

Rigel Announces Results From Phase 3 Trial Of Warm Autoimmune Hemolytic Anemia Treatment

Published: 06/08/2022 11:09 GMT
Rigel Pharmaceuticals (RIGL) - Rigel Announces Top-line Results From Forward Phase 3 Clinical Trial of Fostamatinib in Patients With Warm Autoimmune Hemolytic Anemia.
Rigel Pharmaceuticals Inc - Trial Did Not Demonstrate Statistical Significance in Primary Efficacy Endpoint.
Rigel Pharmaceuticals - Plans to Continue Analyzing Data to Understand Geographical Differences in Patient Disease Characteristics and Outcomes.
Rigel Pharmaceuticals Inc - Safety and Tolerability Profile in Forward Trial Was Consistent With Existing Fostamatinib Safety Database.
Rigel Pharmaceuticals Inc - There Were Five Deaths on Study, All of Which Were Determined to Be Unrelated to Study Drug.
Revenue is expected to be $23.82 Million
Adjusted EPS is expected to be -$0.12

Next Quarter Revenue Guidance is expected to be $21.95 Million
Next Quarter EPS Guidance is expected to be -$0.14

More details on our Analysts Page.